5-Fluorouracil's cytotoxicity is enhanced both in vitro and in vivo by concomitant treatment with hyperthermia and dipyridamole.

Abstract:

:We obtained evidence that the cytotoxic effect of 5-fluorouracil (5-FU) is augmented when the drug is given in combination with hyperthermia (HYP) and dipyridamole (DP). Nontoxic levels of DP enhanced the combined cytotoxicity of 5-FU and HYP against B16 melanoma and human tumor cells in vitro as measured by the succinate dehydrogenase inhibition (SDI) test. Growth of B16 melanoma that had been subcutaneously implanted into the feet of C57 BL mice was inhibited by treatment with the combinations of 5-FU and HYP, of 5-FU and DP, and of 5-FU, HYP and DP as compared with the administration of 5-FU alone. Treatment with HYP plus DP did not alter the body weight of mice that received 5-FU. The administration of DP plus HYP seemed to render the tumor cells more sensitive to 5-FU. The combination of 5-FU, HYP and DP shows promise for the treatment of patients suffering from malignant disease.

authors

Maehara Y,Sakaguchi Y,Takahashi I,Yoshida M,Kusumoto H,Masuda H,Sugimachi K

doi

10.1007/BF00685941

keywords:

subject

Has Abstract

pub_date

1992-01-01 00:00:00

pages

257-60

issue

4

eissn

0344-5704

issn

1432-0843

journal_volume

29

pub_type

杂志文章
  • Potential role of acid ceramidase in conversion of cytostatic to cytotoxic end-point in pancreatic cancer cells.

    abstract:PURPOSE:Acid ceramidase (AC) occupies an important place in the control of cancer cell proliferation. We tested the influence of AC inhibition on the effects of PSC 833, a P-glycoprotein antagonist with potent ceramide-generating capacity, to determine whether AC could be a therapeutic target in pancreatic cancer. MET...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-012-2050-4

    authors: Morad SA,Messner MC,Levin JC,Abdelmageed N,Park H,Merrill AH Jr,Cabot MC

    更新日期:2013-03-01 00:00:00

  • Phase I and pharmacokinetic study of weekly NV06 (Phenoxodiol), a novel isoflav-3-ene, in patients with advanced cancer.

    abstract:BACKGROUND:We wished to define the maximum tolerated dose (MTD), toxicity, and pharmacokinetics of the novel isoflav-3-ene, NV06 (Phenoxodioltrade mark), a compound with a diphenolic structure related chemically and biologically to genistein and flavopiridol. PATIENTS AND METHODS:Twenty-one patients with advanced canc...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-006-0189-6

    authors: de Souza PL,Liauw W,Links M,Pirabhahar S,Kelly G,Howes LG

    更新日期:2006-10-01 00:00:00

  • Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line.

    abstract::A human stomach-adenocarcinoma cell line (MKN-45) was selected for resistance to Adriamycin by stepwise exposure to increasing concentrations of this agent. The resulting cell line (MKN/ADR) exhibited a high level of cross-resistance to topoisomerase II (topo II)-targeted drugs such as Adriamycin, mitoxantrone, and et...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s002800050751

    authors: Son YS,Suh JM,Ahn SH,Kim JC,Yi JY,Hur KC,Hong WS,Muller MT,Chung IK

    更新日期:1998-01-01 00:00:00

  • Alkylphosphocholines: influence of structural variation on biodistribution at antineoplastically active concentrations.

    abstract::Hexadecylphosphocholine (HPC) and octadecylphosphocholine (OPC) show very potent antitumor activity against autochthonous methylnitrosourea-induced mammary carcinomas in rats. The longer-chain and unsaturated homologue erucylphosphocholine (EPC) forms lamellar structures rather than micelles, but nonetheless exhibits ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00686401

    authors: Kötting J,Berger MR,Unger C,Eibl H

    更新日期:1992-01-01 00:00:00

  • Methotrexate removal during haemodialysis in a patient with advanced laryngeal carcinoma.

    abstract::A 62-year-old patient on long-term haemodialysis who developed an inoperable T2N3Mo squamous-cell carcinoma of the larynx was treated with weekly low-dose methotrexate (MTX) after failing to respond to radiotherapy. The patient was initially given one dose of 10 mg MTX (6 mg/m2) as a 1-h infusion, then he received thr...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s002800050528

    authors: Thomson AH,Daly M,Knepil J,Harden P,Symonds P

    更新日期:1996-01-01 00:00:00

  • A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement.

    abstract::Detailed pharmacokinetic analysis and subsequent evaluation of myelotoxicity were performed in 55 patients who had been randomized to 4 different doses of epirubicin (40, 60, 90 or 135 mg/m2 given i.v. every 3 weeks). A significantly positive correlation was demonstrated between the AUC and the myelotoxicity of epirub...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF00685824

    authors: Jakobsen P,Bastholt L,Dalmark M,Pfeiffer P,Petersen D,Gjedde SB,Sandberg E,Rose C,Nielsen OS,Mouridsen HT

    更新日期:1991-01-01 00:00:00

  • Increased cancericidal activity of PTT.119, a new synthetic bis-(2-chloroethyl)amino-L-phenylalanine derivative with carrier amino acids. I. In vitro cytotoxicity.

    abstract::A new synthetic tripeptide (p-F-Phe-m-bis-(2-chloroethyl)amino-Phe-Met ethoxy HCl), PTT.119, was demonstrated to have significant cancericidal activity against seven in vitro tumor cell lines of different origins and etiologies and against primary human AMML, ALL, and hairy cell leukemias. Viabilities of each murine t...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00254592

    authors: Yagi MJ,Bekesi JG,Daniel MD,Holland JF,De Barbieri A

    更新日期:1984-01-01 00:00:00

  • Antagonism of oestrogen action in human breast and endometrial cells in vitro: potential novel antitumour agents.

    abstract:PURPOSE:There is a need to find novel oestrogen receptor (ER) ligands that antagonize oestrogen action in the reproductive tissues and would therefore have therapeutic potential in oestrogen-dependent tumours. We tested novel ER ligands in both breast and endometrial cells to profile agonism/antagonism in these oestrog...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s002800000259

    authors: Nuttall ME,Pendrak I,Emery JG,Nadeau DP,Fisher PW,Nicholson TA,Zhu Y,Suva LJ,Kingsbury WD,Gowen M

    更新日期:2001-05-01 00:00:00

  • Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat.

    abstract:BACKGROUND:In a phase I clinical trial of oxaliplatin (OPT) in combination with paclitaxel (PXL), a pharmacokinetic interaction was observed when OPT was given as a 2-h i.v. infusion followed by a 1-h i.v. infusion of PXL. The purpose of this study was to use a rat model to evaluate whether the pharmacokinetic interact...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-002-0531-6

    authors: Liu J,Kraut EH,Balcerzak S,Grever M,D'Ambrosio S,Chan KK

    更新日期:2002-12-01 00:00:00

  • Phase I-II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer.

    abstract::Lanreotide (BIM 32014), a somatulin analogue, was found to be as effective as castration in a rat prostate tumor model. Therapeutic benefit was also demonstrated in the hormone-resistant phase of this tumor model. The activity of lanreotide may be due to a reduction in the levels of growth factors such as insulin grow...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1007/BF00685857

    authors: Maulard C,Richaud P,Droz JP,Jessueld D,Dufour-Esquerré F,Housset M

    更新日期:1995-01-01 00:00:00

  • Irinotecan induces enterocyte cell death and changes to muc2 and muc4 composition during mucositis in a tumour-bearing DA rat model.

    abstract::Irinotecan-induced mucositis is a major oncological problem. Goblet cells secrete mucus, protecting the intestinal mucosa, with secretion altered during mucositis. The enteric nervous system is involved in regulating gut motility and secretion. The aim of this study was to determine whether enteric neural cells and go...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-019-03787-5

    authors: Thorpe D,Sultani M,Stringer A

    更新日期:2019-05-01 00:00:00

  • Genistein combined with FOLFOX or FOLFOX-Bevacizumab for the treatment of metastatic colorectal cancer: phase I/II pilot study.

    abstract:BACKGROUND:Epidemiologic and preclinical data suggest isoflavones have anticancer activity in colorectal malignancy prevention and treatment. This is the first clinical trial assessing safety and tolerability of Genistein in combination with chemotherapy in metastatic colorectal cancer. METHODS:Patients who had histol...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-019-03886-3

    authors: Pintova S,Dharmupari S,Moshier E,Zubizarreta N,Ang C,Holcombe RF

    更新日期:2019-09-01 00:00:00

  • Pharmacodynamic modeling of prolonged administration of etoposide.

    abstract:PURPOSE:A refined pharmacodynamic model for toxicity is necessary for successful adaptive control of the administration of an anticancer drug to avoid toxicity. We sought to establish a pharmacodynamic model of leukopenia in a 14-day administration of etoposide. METHODS:Pharmacokinetic data of 32 patients treated with...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1007/s002800050538

    authors: Minami H,Ratain MJ,Ando Y,Shimokata K

    更新日期:1996-01-01 00:00:00

  • Plasma and brain pharmacokinetics of letrozole and drug interaction studies with temozolomide in NOD-scid gamma mice and sprague dawley rats.

    abstract:PURPOSE:The aromatase inhibitor, letrozole, is being investigated in experimental animal models as a novel treatment for high-grade gliomas (HGGs). To facilitate optimal dosing for such studies, we evaluated the plasma and brain pharmacokinetics (PK) of letrozole in NOD-scid gamma (NSG) mice, which are frequently emplo...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-018-3705-6

    authors: Arora P,Adams CH,Gudelsky G,DasGupta B,Desai PB

    更新日期:2019-01-01 00:00:00

  • Effects of cyclosporine A on the hepatobiliary disposition and hepatic uptake of etoposide in an isolated perfused rat liver model.

    abstract:PURPOSE:A recirculating isolated perfused rat liver model was used to investigate the hepatobiliary disposition of etoposide and the effects of cyclosporine A (CyA) on the pattern of drug disposition in the bile and uptake in the liver. METHODS:The portal vein, bile duct, and superior vena cava were cannulated in four...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-015-2719-6

    authors: Khezrian M,Sheikholeslami B,Dadashzadeh S,Lavasani H,Rouini M

    更新日期:2015-05-01 00:00:00

  • Cimetidine attenuates vinorelbine-induced phlebitis in mice by militating E-selectin expression.

    abstract:PURPOSE:We investigated E-selectin expression in mice and rabbits with vinorelbine-induced phlebitis and the effect of cimetidine. To find the relationship between E-selectin expression and vinorelbine-induced phlebitis. METHODS:Mouse and rabbit model of vinorelbine-induced phlebitis was established by intravenous inf...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-014-2487-8

    authors: Wang Z,Ma L,Wang X,Cai H,Huang J,Liu J,Hu J,Su D

    更新日期:2014-08-01 00:00:00

  • Studies on the mechanism of 3-deazaguanine cytotoxicity in L1210-sensitive and -resistant cell lines.

    abstract::3-Deazaguanine (3-DG), a purine analogue, has unusual antitumor activity against experimental mammary tumor models and a number of other solid tumors. Others have shown that mutant CHO cells deficient in hypoxanthine guanine phosphoribosyl transferase (HGPRTase) or adenine phosphoribosyl transferase (APRTase) are resi...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00273409

    authors: Singh G,Luna MK,Ardalan B

    更新日期:1988-01-01 00:00:00

  • A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors.

    abstract:PURPOSE:Determine the toxicity, maximum tolerated dose (MTD), and pharmacokinetics of paclitaxel poliglumex (PPX; CT-2103) in combination with cisplatin administered every 3 weeks. PATIENTS AND METHODS:Forty-three patients with advanced solid tumors were treated at escalating doses of PPX with a fixed dose of cisplati...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-008-0813-8

    authors: Verschraegen CF,Skubitz K,Daud A,Kudelka AP,Rabinowitz I,Allievi C,Eisenfeld A,Singer JW,Oldham FB

    更新日期:2009-04-01 00:00:00

  • High-dose adriamycin (ADM) and cis-platinum (DDP) in advanced soft-tissue sarcomas and invasive thymomas. A pilot study.

    abstract::Eighteen previously untreated patients with advanced unresectable or metastatic soft-tissue sarcomas (STS) and two patients with locally invasive thymoma were treated with a combination of adriamycin (ADM) 80 mg/m2 on day 1 and cis-platinum (DDP) 120 mg/m2 on day 1. The regimen was repeated at 4-weeks intervals. In ST...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00257118

    authors: Klippstein TH,Mitrou PS,Kochendörfer KJ,Bergmann L

    更新日期:1984-01-01 00:00:00

  • Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx®).

    abstract:PURPOSE:Pegylated liposomal doxorubicin (PLD) is used to treat patients with breast and gynecological cancers. In order to optimize treatment with PLD, we assessed the prognostic and predictive factors for efficacy of PLD. METHODS:Seventeen patients treated with PLD 30 or 40 mg/m(2) underwent pharmacokinetic sampling ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-014-2514-9

    authors: Boers-Sonderen MJ,van Herpen CM,van der Graaf WT,Desar IM,van der Logt MG,de Beer YM,Ottevanger PB,van Erp NP

    更新日期:2014-09-01 00:00:00

  • Coadministration of vindesine with high-dose methotrexate therapy increases acute kidney injury via BCRP, MRP2, and OAT1/OAT3.

    abstract:PURPOSE:To investigate whether coadministration of vindesine is a risk factor for acute kidney injury caused by high-dose methotrexate in patients with hematologic malignancies and identify its mechanism. METHODS:A retrospective analysis was conducted on 211 cycles of HD-MTX therapy in 178 patients with hematological ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-019-03972-6

    authors: Huang C,Xia F,Xue L,Liu L,Bian Y,Jin Z,Miao L

    更新日期:2020-02-01 00:00:00

  • Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data.

    abstract::Aging influences the disposition and effects of several classes of drugs. Although drug clearance rate is correlated with toxicity for many anticancer drugs, few data have been published concerning the relationship of aging and clearance of chemotherapy. This study was performed to identify any relationship between ag...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,meta分析

    doi:10.1007/BF00686507

    authors: Borkowski JM,Duerr M,Donehower RC,Rowinsky EK,Chen TL,Ettinger DS,Grochow LB

    更新日期:1994-01-01 00:00:00

  • Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer.

    abstract:PURPOSE:This study evaluated the tolerability, pharmacokinetics, and preliminary antitumor activity of EZN-2208, a water-soluble poly(ethylene) glycol conjugate of SN38. METHODS:Patients with advanced malignancies were enrolled in dose-escalating cohorts (3 + 3 design). EZN-2208 was administered as a 1-h intravenous i...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s00280-013-2149-2

    authors: Patnaik A,Papadopoulos KP,Tolcher AW,Beeram M,Urien S,Schaaf LJ,Tahiri S,Bekaii-Saab T,Lokiec FM,Rezaï K,Buchbinder A

    更新日期:2013-06-01 00:00:00

  • A pharmacodynamically guided dose selection of PF-00337210 in a phase I study in patients with advanced solid tumors.

    abstract:PURPOSE:PF-00337210 is an oral, highly selective vascular endothelial growth factor receptor (VEGFR) inhibitor. We evaluated a composite of biomarkers in real time to identify the recommended phase 2 dose (RP2D) and preliminary anticancer activity of PF-00337210. PATIENTS AND METHODS:Patients (Pts) with advanced cance...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-016-2958-1

    authors: Bruce JY,LoRusso PM,Goncalves PH,Heath EI,Sadowski E,Shalinsky DR,Zhang Y,Traynor AM,Breazna A,Ricart AD,Tortorici M,Liu G

    更新日期:2016-03-01 00:00:00

  • A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridine.

    abstract:PURPOSE:Inhibitors of DNA (cytosine-5)-methyltransferases (DNMT) are active antineoplastic agents. We conducted the first-in-human phase I trial of 5-fluoro-2'-deoxycytidine (FdCyd), a DNMT inhibitor stable in aqueous solution, in patients with advanced solid tumors. Objectives were to establish the safety, maximum tol...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s00280-014-2674-7

    authors: Newman EM,Morgan RJ,Kummar S,Beumer JH,Blanchard MS,Ruel C,El-Khoueiry AB,Carroll MI,Hou JM,Li C,Lenz HJ,Eiseman JL,Doroshow JH

    更新日期:2015-03-01 00:00:00

  • Biological evaluation of a novel sorafenib analogue, t-CUPM.

    abstract::Sorafenib (Nexavar®) is currently the only FDA-approved small molecule targeted therapy for advanced hepatocellular carcinoma. The use of structural analogues and derivatives of sorafenib has enabled the elucidation of critical targets and mechanism(s) of cell death for human cancer lines. We previously performed a st...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-014-2626-2

    authors: Wecksler AT,Hwang SH,Liu JY,Wettersten HI,Morisseau C,Wu J,Weiss RH,Hammock BD

    更新日期:2015-01-01 00:00:00

  • Intravenous paclitaxel against metastasis of human gastric tumors of diffuse type.

    abstract:PURPOSE:Gastric cancer is one of the leading cancerous diseases worldwide. It is diagnosed often at the advanced stage for which chemotherapy is the main treatment option. The prognosis remains poor for metastatic, especially the diffuse type, gastric cancers. We investigated the efficacy of intravenously administered ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-009-1222-3

    authors: Tuan TF,Tsai ML,Yeh KC,Huang HC,Chung CT,Huang CL,Han CH,Chen CP,Wang MH,Shen CC,Lai YK,Lee WS,Hwang LL,Chen CT

    更新日期:2010-09-01 00:00:00

  • Weekly docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck.

    abstract:BACKGROUND:The objective of the study was to investigate the efficacy and tolerability of weekly docetaxel in patients with platinum-refractory recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). METHODS:Patients fulfilling the following criteria were enrolled: histologically confirmed SCCHN;...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1007/s00280-009-0999-4

    authors: Cho BC,Keum KC,Shin SJ,Choi HJ,Lee YJ,Kim SH,Choi EC,Kim JH

    更新日期:2009-12-01 00:00:00

  • Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).

    abstract:PURPOSE:To explore the safety and tolerability of combining two epigenetic drugs: decitabine (a DNA methyltransferase inhibitor) and panobinostat (a histone deacetylase inhibitor), with chemotherapy with temozolomide (an alkylating agent). The purpose of such combination is to evaluate the use of epigenetic priming to ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-014-2501-1

    authors: Xia C,Leon-Ferre R,Laux D,Deutsch J,Smith BJ,Frees M,Milhem M

    更新日期:2014-10-01 00:00:00

  • Incorporation of OSI-7836 into DNA of Calu-6 and H460 xenograft tumors.

    abstract::OSI-7836 (4'-thio-beta-D-arabinofuranosylcytosine) is a novel nucleoside analog in phase I clinical development for the treatment of cancer. As with other nucleoside analogs, the proposed mechanism of action involves phosphorylation to the triphosphate form followed by incorporation into cellular DNA, leading to cell ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-004-0844-8

    authors: Richardson F,Black C,Richardson K,Franks A,Wells E,Karimi S,Sennello G,Hart K,Meyer D,Emerson D,Brown E,LeRay J,Nilsson C,Tomkinson B,Bendele R

    更新日期:2005-03-01 00:00:00